Summary: Johnson & Johnson demonstrates better R&D efficiency and has a larger patent portfolio compared
Summary: Pfizer has experienced a total return loss of nearly -40% so far in 2023,
Summary: Pfizer has underperformed the S&P 500, healthcare stocks, and high-yield stocks since 2013. The
Summary: Today’s news that Pfizer Inc.’s twice-daily oral weight loss drug will be discontinued due
Summary: It’s always and forever a market of stocks, not a stock market. The Nasdaq
Summary: When I saw Pfizer Inc. stock settling below pre-pandemic levels, I knew the deterioration
Summary: The market is pricing Pfizer like a perpetual no-growth stock. There are many reasons
Summary: A list of high-quality dividend growth stocks is identified based on proximity to 52-week
Summary: Pfizer’s stock has dropped due to a decline in revenues post-COVID, presenting a value
Summary: Pfizer’s stock has underperformed the market due to declining revenue and profits on a